Hand-foot-and-mouth disease
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
all patients
analgesics and antipyretics
Simple oral analgesics and antipyretics such as paracetamol and ibuprofen may be used to lower fever and relieve pain.
Aspirin is not recommended for fever due to its association with Reye's syndrome.
Primary options
paracetamol: children <12 years of age: 15 mg/kg orally every 4-6 hours when required, maximum 75 mg/kg/day; children >12 years of age: 500-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
OR
ibuprofen: children <12 years of age: 5-10 mg/kg orally every 6-8 hours when required, maximum 40 mg/kg/day; children >12 years of age: 300-400 mg every 6-8 hours when required, maximum 2400 mg/day
topical anaesthetics
Additional treatment recommended for SOME patients in selected patient group
Lidocaine can be used topically as an initial treatment for small, sparse mouth ulcers.
A mixture of aluminium and magnesium hydroxide, diphenhydramine, and viscous lidocaine with or without sucralfate can also be used topically for symptomatic pain control of mouth ulcers. A pharmacist must be consulted to make up this mixture.
Swishing elixir or mixture around in the mouth is not suitable for young children; elixir should be applied using a cotton-tipped applicator.
Primary options
lidocaine topical: (2% viscous solution) apply to the affected area(s) with a cotton-tip applicator up to three times daily when required
adequate fluid and nutritional intake
Additional treatment recommended for SOME patients in selected patient group
Maintaining adequate fluid and nutritional intake is important but may be difficult in patients with oral ulcers.
For children with moderate-to-severe dehydration, intravenous hydration may be necessary.
hospitalisation and supportive treatment
Treatment recommended for ALL patients in selected patient group
Complications are rare. Hospitalisation and supportive treatment for complications is likely to be required for these patients.
The complications that can occur with enterovirus 71 (EV71) infection include aseptic meningitis, encephalitis, encephalomyelitis, pulmonary oedema, pulmonary haemorrhage, myocarditis, a polio-like syndrome, and death.[7]Chang LY, Tsao KC, Hsia SH, et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA. 2004;291:222-227. http://jama.ama-assn.org/cgi/content/full/291/2/222 http://www.ncbi.nlm.nih.gov/pubmed/14722149?tool=bestpractice.com [8]Chang LY, Huang LM, Gau SS, et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med. 2007;356:1226-1234. http://www.nejm.org/doi/full/10.1056/NEJMoa065954#t=article http://www.ncbi.nlm.nih.gov/pubmed/17377160?tool=bestpractice.com [9]Chang LY, Lin TY, Huang YC, et al. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J. 1999;18:1092-1096. http://www.ncbi.nlm.nih.gov/pubmed/10608631?tool=bestpractice.com [10]Lee TC, Guo HR, Su HJ, et al. Diseases caused by enterovirus 71 infection. Pediatr Infect Dis J. 2009;28:904-910. http://www.ncbi.nlm.nih.gov/pubmed/20118685?tool=bestpractice.com
In immunocompromised patients, symptoms may be more severe and prolonged.
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer